Table 1 Demographics and other characteristics of the study participants. Data are presented as median (interquartile range), unless indicated otherwise
Controls (n = 10) | Rivaroxaban (n = 10) | Apixaban (n = 10) | Edoxaban (n = 10) | Dabigatran (n = 10) | Phenprocoumon (n = 10) | LMWH (n = 10) | UFH (n = 10) | |
|---|---|---|---|---|---|---|---|---|
Female/male gender, n (%) | 6/4 (60/40) | 5/5 (50/50) | 8/2 (80/20) | 9/1 (90/10) | 8/2 (80/20) | 6/4 (60/40) | 6/4 (60/40) | 3/7 (30/70) |
Age (years) | 60 (58–64) | 71 (54–81) | 82 (79–87) | 77 (73–83) | 72 (58–79) | 82 (45–86) | 70 (42–79) | 74 (63–82) |
BMI (kg/m2) | 27.1 (25.6–30.7) | 23.7 (22.0–31.7) | 23.9 (23.2–26.0) | 27.0 (24.0–29.2) | 26.3 (23.6–29.5) | 26.6 (24.6–30.2) | 24.3 (20.3–28.1) | 26.6 (22.0–27.9) |
ASA status, n (%) | ||||||||
1 | 2 (20) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 8 (80) | 2 (20) | 0 | 0 | 3 (30) | 0 | 1 (10) | 0 |
3 | 0 | 8 (80) | 10 (100) | 10 (100) | 7 (70) | 10 (100) | 9 (90) | 9 (90) |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (10) |
Diabetes, n (%) | ||||||||
Yes | 0 | 2 (20) | 2 (20) | 2 (20) | 2 (20) | 4 (40) | 1 (10) | 3 (30) |
No | 10 (100) | 8 (80) | 8 (80) | 8 (80) | 8 (80) | 6 (60) | 9 (90) | 6 (70) |
Creatinine (mg/dL) | 0.9 (0.78–0.95) | 1.0 (0.89–1.49) | 1.2 (1.2–1.4) | 1.2 1.1–1.4) | 1.1 (0.9–1.3) | 1.5 (1.1–2.6) | 1.1 (0.88–1.4) | 1.0 (0.6–2.5) |
GFR (ml/min) | 96 (93–106) | 79 (65–99) | 56 (48–82) | 71 (52–81) | 74 (64–104) | 61 (35–84) | 92 (70–112) | 73 (23–86) |
Platelets (109/L) | 262 (210–289) | 214 (141–265) | 247 (159–294) | 220 (180–271) | 229 (184–293) | 239 (170–266) | 282 (211–330) | 227 (156–350) |
Hb (mg/dL) | 14.3 (13.7–15.2) | 12.5 (10.0–14.6) | 11.8 (9.9–13.6) | 13.1 (11.9–14.1) | 13.6 (11.4–15.1) | 12.2 (10.7–15.3) | 11.0 (9.4–12.6) | 8.3 (7.4–9.1) |
Hematocrit | 0.41 (0.39–0.43) | 0.38 (0.31–0.43) | 0.36 (0.3–0.41) | 0.38 (0.37–0.41) | 0.40 (0.34–0.44) | 0.36 (0.32–0.45) | 0.31 (0.28–0.35) | 0.26 (0.22–0.28) |
Fibrinogen (mg/dL) | 367 (325–411) | 413 (359–447) | 530 (366–594) | 481 (310–570) | 365 (298–425) | 420 (390–500) | 429 (341–597) | 414 (319–509) |